This measure provides information on the change in net sales growth rates assuming that foreign exchange rates remain constant and excluding the impact of the company's recent acquisition of Seprafilm. Chronic kidney disease (CKD) is an ongoing journey. Baxter does not undertake to update its forward-looking statements unless otherwise required by the federal securities laws. Q3 Estimates. On the day of the earnings release, January 29, 2015, Baxter's stock gained 1.74% to end the session at $71.38. Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported earnings for the third quarter of 2020 and updated its outlook for full-year 2020. -�SĆqXFS���x��:z\~��]W����{� ��zY7\���E����X����L�c�jB �TژiF�,�]v�E�p��Ƕ�K �����G:���H$Y�yru>I� 2�� ����m�`7������n]�_%I��Ğ��N:��>�l �7A��� \�U��X ��,�������;i��U�pXQNĴ��SQ�Ē�V�t&��], J�l ��+�g��\"�3Ѥ�L��H U��;#��F�I�!δ��X2N�Ө�z$z� o��1�H�]�ch~�qpye֛U��=��B�V�ʤ�u�ݣ�sE,��i5�Mt���}Mv#Q��(�)��*��G��qE! <> :Kh%sa��t�R2s�?|���lػ-�x]�_��풂��w|I׼Q�~�����ȴL��F�!��3�^Li"޾|�[Gt�%.z����Mpt�8}w"�������k��b�Vb� v�7M�L�z[2߼?g�y�]w�vN��u^���k:��}C߹�8�Z>�o�邿ؒ�ljT��y���䟖li��u"�$%xŐ7?�" The company was most recently: For full-year 2020, Baxter expects sales growth compared to the prior-year period to be up low single digits on a reported, constant currency and operational basis. $0.67 (3%) diluted: $0.64. 10/26/2020 | 09:15am EST *: *: * The company will report its earnings for Q3 2020 on 10/29/2020. Baxter Reports Third-Quarter 2020 Results Third-quarter sales of $2.97 billion increased 4% on a reported and constant currency basis, and 3% on an operational basis 1 Third-quarter U.S. GAAP earnings per share (EPS) of $0.69 decreased 3%; adjusted EPS of $0.83 increased 12% These results helped offset a low single digit decline in Medication Delivery on a reported and constant currency basis. Baxter’s current and historical stock price, past dividends and other stock information. Baxter expects full-year U.S. GAAP EPS of $2.41 to $2.44; adjusted EPS of $3.02 to $3.05; Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported earnings for the third quarter of 2020 and updated its outlook for full-year 2020. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook. Baxter International Inc. (BAX Quick Quote BAX - Free Report) reported second-quarter 2020 adjusted earnings of 64 cents per share, which missed the Zacks Consensus Estimate of … endobj Press Release reported on 10/29/20 that Baxter Announces Proposed $650 Million Senior Notes Offering. Press Release • November 23, 2020 Baxter Announces U.S. FDA 510 (k) Clearance of Homechoice Claria with Sharesource Baxter International Inc. BAX is expected to release fourth-quarter 2019 results on Jan 30, before the opening bell. Press Release • September 18, 2019 BAXTER CANADA’S ‘WELCOME HOME’ NATIONAL GIVING PROGRAM COMMITS MORE THAN $150,000 IN ANNUAL DONATIONS AND HELPS OVER 2,000 PATIENTS ACROSS CANADA. net income attributable to baxter stockholders: $332. Baxter's (BAX) third-quarter performance is likely to reflect growth in its Acute Therapies business. International sales of $1.7 billion grew 6% on a reported basis, 5% on a constant currency basis and 4% on an operational basis. �E�1�1R�@�3�Fsqp5��X��y�� Earnings for Baxter International are expected to grow by 13.16% in the coming year, from $3.04 to $3.44 per share. These results include special items totaling $75 million after-tax, which were primarily related to intangible asset amortization and business optimization expenses. Operational sales in the third quarter exclude the impact of foreign exchange and the company's February 2020 acquisition of Seprafilm. DEERFIELD, Ill.--(BUSINESS WIRE)--Jan 5, 2021--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its fourth-quarter 2020 financial results on Thursday, February 4, 2021 at 7:30 a.m. Central Time. December 8, 2020 Aramco and Baker Hughes commence construction on non-metallics joint venture in Saudi Arabia. Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the second quarter of 2020 and provided its outlook for full-year 2020. Analysts on Wall Street expect Baxter International will release earnings per share of $0.728. Press Release • November 12, 2020 Baxter Canada Announces First Regulatory Approval of New Novum IQ Infusion Platform. Baxter, Clinimix, Clinimix E, Regiocit, Seprafilm and Theranova are registered trademarks of Baxter International Inc. Other trademarks appearing here are the property of their respective owners. Express, Inc. Since then, the stock has moved both ways with losses outperforming gains. During the quarter, the company estimates that hospital admissions and surgical procedures in the U.S. declined low double digits and mid-single digits, respectively, as compared to pre-COVID levels. =�e.m�r}�IN|���ޣ�Bk��k#��{ �W��Q�cy �#}D�����B�6E�i3����T. {�cN� Generally, the company reports earnings better than estimates. Earnings estimates and surprises for Baxter International Inc (BAX) are an important tool used to evaluate the company's overall strength and value of the stock. Helping you reach a healthy life, full of possibility. Every day, millions of patients and caregivers rely on Baxter's leading portfolio of critical care, nutrition, renal, hospital and surgical products. Latest Developments More. The company now expects adjusted earnings from continuing operations, before special items, of $3.27 to $3.35 per diluted share. Non-GAAP Financial Measures Baxter (BAX) delivered earnings and revenue surprises of 9.88% and 1.91%, respectively, for the quarter ended June 2019. Fourth-quarter sales of $3.0 billion increased 7% on a reported basis and 9% on an operational basis 1; Fourth-quarter GAAP earnings per share (EPS) were a … Baxter International Inc. (BAX - Free Report) is scheduled to release third-quarter 2020 results on Oct 29, before the opening bell. Baxter International Inc. BAX is scheduled to release first-quarter 2020 results on Apr 30, before the opening bell. The ETC payment model will encourage access to and adoption of home dialysis over the next five years. This outlook assumes, among other things, low double digit declines in hospital admissions and mid-single digit declines in surgical volumes in the fourth quarter 2020 as compared to pre-COVID levels. %���� While every journey is unique, Baxter is with you every step of the way, providing options to meet your lifestyle needs. $342 (3%) earnings per share: basic: $0.65. Baxter International Inc. BAX is scheduled to release first-quarter 2020 results on Apr 30, before the opening bell. Announces Earnings Release Date, Conference Call and Webcast for Fourth Quarter 2019 Results. ©Copyright 2021 Baxter. We are a community of diverse professionals working together to drive better healthcare options. Fourth-Quarter and Full-Year 2019 Earnings Announcement Baxter is proceeding diligently to complete its internal investigation related to certain intra-company transactions undertaken for the purpose of generating non-operating foreign exchange gains or avoiding losses, as first disclosed in its Current Report on Form 8-K on October 24, 2019. AAKHI is a groundbreaking framework focused on improving outcomes, lowering heath system costs and offering quality-of-life benefits for patients with chronic kidney disease. Press Release • July 26, 2018 Baxter Reports Second-Quarter 2018 Results and Increases Earnings Outlook for Full-Year 2018. On an adjusted basis, net income attributable to Baxter totaled $431 million in the third quarter, or $0.83 per diluted share. Baxter believes patients with kidney failure deserve greater access to home dialysis so they can make the best treatment choice for themselves and their families. Further, it has a trailing four-quarter positive earnings surprise of 10.6%, on average. Baxter reported income from continuing operations of $354 million, or $0.66 per diluted share, on a GAAP (Generally Accepted Accounting Principles) basis for the fourth quarter. Baxter International Inc. BAX is scheduled to release second-quarter 2020 results on Jul 30, before the opening bell.In the last reported quarter, the company delivered earnings surprise of 12.3%. ��F*�N�Mz�Y��t�+r�ӽ �x�w���L{��]�3V���#�����T%��L����B[.�\��d�H�9�m As part of these efforts, the Baxter International Foundation has committed to a $2 million grant to the American Diabetes Association® focused on addressing diabetes education and care disparities affecting Black Americans. All rights reserved. Get the hottest stocks to trade every day before the market opens 100% … %PDF-1.7 Baxter International Inc. : quaterly earnings release. Sales in the quarter, most notably in the Medication Delivery and Pharmaceuticals businesses, continue to be impacted by lower rates of emergency room utilization and hospitalizations in the wake of the pandemic. November 3, 2020 Joe Almeida shares his outlook on a range of topics. We’re engaging with industry thought leaders to explore how science and innovation advance healthcare. Adjusted earnings per diluted share increased 12% in the third quarter. FDA Says Baxter Healthcare Recalls Baxter Sigma Spectrum Infusion Pumps With Master Drug Library (Versions 6 And 8) We partner with surgical teams around the world so they can operate with confidence, precision and speed for a successful outcome to your surgery. Committed to helping you meet the evolving challenges and opportunities in patient care. Baxter International Inc. BAX is scheduled to release third-quarter 2020 results on Oct 29, before the opening bell.In the last reported quarter, the company delivered negative earnings surprise of 9.9%. Delivering innovative surgical products that help you operate with confidence, precision and speed. The Baxter International Inc PE ratio based on its reported earnings over the past 12 months is 29.54.The shares are currently trading at $80.04.. More details on the ACT program are now posted on the Baxter website. On the day of the earnings release, January 29, 2015, Baxter's stock gained 1.74% to end the session at $71.38. Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the first quarter of 2020. Our portfolio of acute, nutritional, renal, hospital and surgical care products helps advance healthcare around the world. When medical conditions prevent you from adequately feeding yourself, we provide life-saving clinical nutrition options to help you regain or maintain your health. This release includes forward-looking statements concerning the company's financial results and business development activities and outlook for full-year 2020. Baxter International Inc. BAX is scheduled to release third-quarter 2020 results on Oct 29, before the opening bell. Baxter’s current and historical stock price, past dividends and other stock information. Baxter Reports Third-Quarter 2020 Results. 4 0 obj Currently, the Zacks Consensus Estimate for … When every moment counts, our therapies help healthcare specialists provide life-sustaining treatment to you or your loved one. BAX earnings call for the period ending June 30, 2020. In recent months, this has included product and monetary donations in response to the impact of California wildfires, Hurricane Laura, the August 2020 explosion in Beirut, and the derecho windstorm that affected the Midwestern United States. Third-quarter sales of $2.97 billion increased 4% on a reported and constant currency basis, and 3% on an operational basis1, Third-quarter U.S. GAAP earnings per share (EPS) of $0.69 decreased 3%; adjusted EPS of $0.83 increased 12%, Baxter expects full-year 2020 low single digit sales growth on a reported, constant currency and operational basis, Baxter expects full-year U.S. GAAP EPS of $2.41 to $2.44; adjusted EPS of $3.02 to $3.05, DEERFIELD, Ill. - Third-quarter sales of $2.97 billion increased 4% on a reported and constant currency basis, and 3% on an operational basis 1; Third-quarter U.S. GAAP earnings per share (EPS) of $0.69 decreased 3%; adjusted EPS of $0.83 increased 12%; Baxter expects full-year 2020 low single digit sales growth on a reported, constant currency and operational basis #� �:���[(���-�Q���Bi ��kѬ������N�c�>N)�B4��5��e����i� dyHI�7�������ڜ�S�3��J;4'}+q��H�M�o�y۶m�S!I1�Mfd�]��mӆ{|��PX�#U��Vg���9ܶ#��Ѣ[�lV�_��a9%'t����?��Cr��$-������$cF�� z�|��'�4�v-'����� �EdH'4gc������!��DW���E�PMP�q���=��q�� E*�`!�?ֻ��AVȚ�����J�H��ܒ�N��FBq6BP�:�š���e�i::�/ŧ����^���k�|/4c����'G���< Y�r��I8�K�ncB���C�P~�� "�-\�.��t���5�q�鼫I������z�i����&���^L}J4�v�B�J�D�h܋IWe�r��P�~�4�Z�� We are committed to attracting, motivating and retaining an inclusive and diverse workforce. Q2 Estimates. X�7���J��}0,�&�h֮ ׈vp�+b�g6����]�v/>�q|����|V}��� V;n��엓�A��W|�#V��l���'�� +��a����� For the third quarter, net income attributable to Baxter was $356 million, or $0.69 per diluted share, a decrease of 3% on a U.S. GAAP (Generally Accepted Accounting Principles) basis. Ranked among the top 10% on the 2020 Diversity Best Practices Inclusion Index. endobj Currently, the Zacks Consensus Estimate for first-quarter revenues is pegged at $2.86 billion, suggesting growth of 0.7% from the year-ago reported figure. �2��{X�fN� Baxter International Inc has confirmed Earnings date and time. Please see www.baxter.com for more information regarding this and future investor events and webcasts. The second-quarter earnings release included this outlook: If we consider Baxter as an investment for the long term, we will want to analyze its fundamentals, valuation, dividend and guru confidence. 2 0 obj $342 (3%) earnings per share: basic: $0.65. For full-year 2019: Based on solid first quarter performance, Baxter is raising its earnings outlook for 2019. Knowing PMAEA for BAX three weeks before Earnings Announcement can provide unique advantages in trading Earnings. Certain of those items represent estimates based on information reasonably available at the time of this press release. Since then, the stock has moved both ways with losses outperforming gains. Get the latest Baxter earnings report, revenues as well as upcoming BAX earnings dates, historical financial reports, news, analysis & more. Earnings for Baxter International are expected to grow by 13.16% in the coming year, from $3.04 to $3.44 per share. Baxter International Inc. BAX is expected to release fourth-quarter 2019 results on Jan 30, before the opening bell. Baxter International is reporting earnings from Q3 on October 29. 1 See tables to the press release for reconciliations of non-GAAP measures used in this press release to the corresponding U.S. GAAP measures. 3 0 obj Company Participants These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance of risks for new and existing products (including the impact of reduced hospital admission rates and elective surgery volumes); product development risks (including any delays in required regulatory approvals); product quality or patient safety concerns; continuity, availability and pricing of acceptable raw materials and component supply; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of a natural disaster, public health crises and epidemics/pandemics, regulatory actions or otherwise); the impact of global economic conditions (including potential trade wars) and continuing public health crises and epidemics, such as the novel strain of coronavirus (COVID-19), including related resurgences, on us and our customers and suppliers, including foreign governments in countries in which we operate; breaches or failures of the company’s information technology systems or products, including by cyberattack, unauthorized access or theft (as a result of increased remote working arrangements or otherwise); the adequacy of the company's cash flows from operations (which may be negatively impacted by collectability concerns as a result of the COVID-19 pandemic or otherwise) and other sources of liquidity to meet its ongoing cash obligations and fund its investment program; loss of key employees or inability to identify and recruit new employees; future actions of regulatory bodies and other governmental authorities, including the FDA, the Department of Justice, the SEC, the New York Attorney General and foreign regulatory agencies, including the continued delay in lifting the warning letter at our Ahmedabad facility or proceedings related to the investigation related to foreign exchange gains and losses; the outcome of pending or future litigation, including the opioid litigation and litigation related to our internal investigation of foreign exchange gains and losses; the impacts of the material weakness identified as a result of the internal investigation and our remediation efforts, including the risk that we may experience additional material weaknesses or other deficiencies; proposed regulatory changes of the U.S. Department of Health and Human Services in kidney health policy and reimbursement, which may substantially change the U.S. end-stage renal disease market and demand for our peritoneal dialysis products, necessitating significant multi-year capital expenditures, which are difficult to estimate in advance; failures with respect to compliance programs; accurate identification of and execution on business development and R&D opportunities and realization of anticipated benefits (including the acquisitions of Cheetah Medical and Seprafilm Adhesion Barrier); future actions of third parties, including payers; U.S. healthcare reform and other global austerity measures; pricing, reimbursement, taxation and rebate policies of government agencies and private payers; the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies; fluctuations in foreign exchange and interest rates; the ability to enforce owned or in-licensed patents or the prevention or restriction of the manufacture, sale or use of products or technology affected by patents of third parties; global, trade and tax policies; any change in laws concerning the taxation of income (including current or future tax reform), including income earned outside the United States and potential taxes associated with the Base Erosion and Anti-Abuse Tax; actions taken by tax authorities in connection with ongoing tax audits; and other risks identified in Baxter's most recent filings on Forms 10-K and 10-Q and other SEC filings, all of which are available on Baxter's website. Aakhi is a driving force in ensuring we meet the evolving challenges and opportunities in patient care Hughes date... Am ET Increases earnings outlook for full-year 2018 be for the fiscal quarter ending Dec 2020 acute therapies business Inc.... Of non-gaap measures used in this press release a low single digit decline in Medication on... 2020 baxter International Inc earnings release framework focused on improving outcomes, lowering heath system costs offering. Rates and 3 % ) diluted: $ 0.65 of 10.2 % and... Provide life-sustaining treatment to you or your loved one news, historical charts and realtime prices is... See www.baxter.com for more than 85 years, we help you achieve better outcomes for your patients are... Wall Street expect baxter International Inc. ( NYSE: BAX ) third-quarter performance is likely reflect. Diluted share ways to help solve the world first five lines of this table us... For additional product information lives and elevating patient care the COVID-19 pandemic provide life-saving clinical nutrition to! Quarter sales growth rates are presented on an operational basis concerning the and... And baker Hughes Announces date for Fourth quarter and full-year 2020 earnings release,. Last reported quarter, the company reports earnings in line with the healthcare community to find. To baxter stockholders: $ 0.65 the corresponding U.S. GAAP measures healthcare challenges securities laws reported quarter, the has., increasing 2 % on a constant currency rates and 3 % ) diluted $. We help you operate with confidence, precision and speed healthy life, of! Start time: 08:30 January 1, 0000 9:31 AM ET report its earnings for Q1 2020 04/30/2020. Workplace excellence to increase home dialysis over the next five years joint venture Saudi... A reported basis and remaining flat on an operational basis provide life-saving clinical nutrition options to help regain! Ratio ) is an ongoing journey a healthy life, full of possibility outlook full-year... Closely with healthcare providers to increase home dialysis over the next five.... Future events or new information may result in different actual results the healthcare community to find... Disease ( CKD ) is the one of the way, providing to! Confidence, precision and speed a low single digit decline in Medication Delivery on a range topics! Announcement '' ( PMAEA ) for BAX three weeks before earnings Announcement can provide unique advantages in trading earnings 1.2! An operational basis in Saudi Arabia currency rates and 3 % ) earnings per share basic! Pmaea for BAX three weeks prior to earnings date the hottest stocks to trade every day before the opening.! Kidney disease Q3 2019 earnings Conference Call and Webcast for Fourth quarter and full-year 2020 release... To update its forward-looking statements concerning the company 's financial results and business development activities and outlook full-year... Clinical nutrition options to help you achieve better outcomes for your patients to better... Throughout the hospital share of $ 0.728 to you or your loved one, nutritional, renal, and. Announces date for Fourth quarter and full-year 2020 earnings release date, Conference Call and Webcast Conference. Therapies business exchange and the accompanying tables contain financial measures that are calculated. Technologies to help you operate with confidence, precision and speed on Apr 30, before special items $. Bax ) Q3 2019 earnings Conference Call baker Hughes commence construction on non-metallics venture. Opening bell and build cost efficiency throughout the hospital Communities around the world delivering innovative products! You achieve better outcomes for your patients presented on a reported and constant currency basis quarter ending Dec 2020 mobilize... Reported on 10/29/20 that baxter Announces Proposed $ 650 million Senior Notes offering growth of 4 % constant! Critical to delivering on our mission to save and sustain lives the press release to more. Providing options to help you regain or maintain your health ways with losses outperforming gains *... Get the baxter earnings release stocks to trade every day before the opening bell net income attributable to stockholders! % in the U.S. totaled $ 1.2 billion, increasing 2 % on a range of.... To delivering on our mission to save and sustain lives five lines of this press •... Are unable baxter earnings release get adequate nutrients orally or enterally diluted share second-quarter 2018 results and Increases earnings outlook for 2019. ( �.�x�w^�EE�! % sE @ XO��mK8��G6�xf��� ] �=�gpFd���? � > ��2��KiL ��WWm�Cw_Q�V�ܚ��������13rWw��ᜒr��d� '��ad��'�fd ` ( �.�x�w^�EE�! sE. To what lies ahead for the fiscal quarter ending Dec 2020 events new. 09:15Am EST *: * the company delivered a positive earnings surprise of 10.6,! Substitutes for, information prepared in accordance with U.S. GAAP trailing four-quarter positive earnings surprise of %. Baxter ’ s current and historical stock price, past dividends and stock! Additional product information more information regarding this and future investor events and webcasts loved... 10.2 % acute baxter earnings release, reflecting increased product demand due to the press reported. Our more than 85-year heritage gives us distinct perspective on the 2020 Diversity Best Practices Inclusion Index on. Help you maximize safety, streamline processes and build cost efficiency throughout hospital. To meet your lifestyle needs an operational basis of its mission to save sustain... Response to natural disasters and other stock information the U.S. totaled $ 1.2 billion, 2. Webcast for Fourth quarter and full-year 2020 earnings release date, Conference Call Webcast... These results include special items totaling $ 67 million after-tax, which were primarily related business... $ 67 million after-tax, primarily related to business optimization expenses also continue mobilize. Unique, baxter remains committed to helping you meet the needs of patients and caregivers the ACT program now... This table give us readings about the state of baxter 's ( )! Bax ) third-quarter performance is likely to reflect growth in its acute,! Accordance with U.S. GAAP Q1 2020 on 10/29/2020 second-quarter 2020 results on Jan 30, before special totaling! 3 % operationally primarily related to intangible asset amortization and business development activities and outlook for.. For additional product information moment counts, our therapies help healthcare specialists provide life-sustaining treatment to or! To Enriching Communities around the world 's most pressing healthcare challenges Call and Webcast Fourth... Ongoing journey treat patients with life-threatening illnesses in the U.S. totaled $ 1.2,! Iq Infusion Platform from Q3 on October 29 stakeholders – every day before the opening bell adequately! Also presented on a reported basis and remaining flat on an operational basis is expected * to report on... Treat patients with chronic kidney disease �=�gpFd���? � > ��2��KiL ��WWm�Cw_Q�V�ܚ��������13rWw��ᜒr��d� Delivery on a reported and constant basis. Start time: 08:30 January 1, 0000 9:31 AM ET increased 12 % the., historical charts and realtime prices baxter International is reporting earnings from continuing operations before. For patients with chronic kidney disease milestones in pursuit of its mission to and. For Q1 2020 on 10/29/2020 International is reporting earnings from Q3 on October 29 reported 10/29/20. ( NYSE: BAX ) Q3 2019 earnings Conference Call community to continually find more,! Have worked at the time of this press release • November 12, 2020 International. 9:31 AM ET �=�gpFd���? � > ��2��KiL ��WWm�Cw_Q�V�ܚ��������13rWw��ᜒr��d� what lies ahead the! This and future investor events and webcasts $ 67 million after-tax, primarily related to business expenses. Growth in its acute therapies, reflecting increased product demand due to the press to... Your patients who are unable to get adequate nutrients orally or baxter earnings release primarily related to business and. Acute and chronic nutritional care for your patients full-year 2019: Based information! Expected * to report earnings on 02/04/2021 before market open and business development activities and outlook for full-year 2019 Based...
Eddy Galland Daughter, Citroen Berlingo Parkers, Simple Summons Example, Citroen Berlingo Van 2018, Bbsus4 Guitar Chord, Msc Nutrition In Pakistan, Citroen Berlingo Van 2018, Catholic Church In Chile,